Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Read more about Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.
Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Read more about Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Read more about Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Read more about Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors.
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Read more about Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Read more about Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas.
Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Read more about Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer.
O6-Methylguanine-DNA methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics. Read more about O6-Methylguanine-DNA methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics.
Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs. Read more about Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.
High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. Read more about High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
